Trevena Inc TRVN

Healthcare Biotechnology

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

OTCPK:TRVN - Post by User

Trevena Inc

Bullboard Posts

Comment by jagsfan2on Mar 20, 2017 7:03pm

56 Views

Post# 26004675

RE:Ohh the PAIN . . . FYI

In my experience they use morphine for a short time(24-36hrs) & then switch the patient onto Tylenol Strong.
Hard to see that they'll switch many patients away from the original pain relief medications in Canada, as they are cheap & accessible.
In the U$, however, healthcare is a major profit maker and everything is billed out at cost plus & if their cost is higher, then the indurance companies will have to pay more.

Bullboard Posts

Sirios Resource discovers visible gold in Quebec